AAIC 2026: Combination Therapy and Multi-Target Approaches in Alzheimer's Disea…

Conference: Alzheimer’s Association International Conference (AAIC) 2026 Dates: July 12-15, 2026 Location: ExCeL London, UK Theme: Building Bridges in Alzheimer’s Research

Executive Summary

flowchart TD
    events_aaic_2026_combination_t["AAIC 2026: Combination Therapy and Multi-Target"]
    style events_aaic_2026_combination_t fill:#4fc3f7,stroke:#333,color:#000
    events_aaic_2026_com_0["Executive Summary"]
    events_aaic_2026_combination_t -->|"includes"| events_aaic_2026_com_0
    style events_aaic_2026_com_0 fill:#81c784,stroke:#333,color:#000
    events_aaic_2026_com_1["Scientific Rationale for Combination Therapy"]
    events_aaic_2026_combination_t -->|"includes"| events_aaic_2026_com_1
    style events_aaic_2026_com_1 fill:#ef5350,stroke:#333,color:#000
    events_aaic_2026_com_2["Why Single-Target Approaches Are Insufficient"]
    events_aaic_2026_combination_t -->|"includes"| events_aaic_2026_com_2
    style events_aaic_2026_com_2 fill:#ffd54f,stroke:#333,color:#000
    events_aaic_2026_com_3["Pharmacological Interactions: Synergy, Additivit"]
    events_aaic_2026_combination_t -->|"includes"| events_aaic_2026_com_3
    style events_aaic_2026_com_3 fill:#ce93d8,stroke:#333,color:#000
    events_aaic_2026_com_4["Lessons from Oncology and Infectious Disease"]
    events_aaic_2026_combination_t -->|"includes"| events_aaic_2026_com_4
    style events_aaic_2026_com_4 fill:#4fc3f7,stroke:#333,color:#000
    events_aaic_2026_com_5["Anti-Amyloid + Anti-Tau Combinations"]
    events_aaic_2026_combination_t -->|"includes"| events_aaic_2026_com_5
    style events_aaic_2026_com_5 fill:#81c784,stroke:#333,color:#000

The approval of lecanemab (Leqembi) and donanemab (Kisunla) has transitioned Alzheimer’s disease from a single-target era into a combination therapy paradigm. At AAIC 2026, the EU/US CTAD Task Force highlighted combination therapy as the central strategic priority for the next decade of AD drug development

This page covers the scientific rationale, active clinical programs, trial design considerations, and regulatory landscape for combination approaches in Alzheimer’s disease.

Scientific Rationale for Combination Therapy

Why Single-Target Approaches Are Insufficient

Alzheimer’s disease involves multiple concurrent pathological processes, and targeting only one mechanism has proven insufficient for robust disease modification^{1Combination Therapy for Neurodegenerative Diseases: A Systematic Review2023 · Journal of Neurochemistry · PMID 37058421Open reference2Multi-target Drug Design for Neurodegenerative Diseases2022 · Nature Reviews Drug Discovery · PMID 35694825Open reference}:

• Protein aggregation: Amyloid-beta plaques, tau neurofibrillary tangles, and their oligomeric intermediates drive distinct but interacting pathways

• Neuroinflammation: Activated microglia, reactive astrocytes, and the complement system contribute to synaptic loss independent of amyloid

• Synaptic dysfunction: Network disruption and interneuron dysfunction occur early and progress even after amyloid clearance

• Metabolic dysregulation: Insulin resistance, lipid dysmetabolism, and mitochondrial dysfunction create a permissive environment for pathology

• Vascular dysfunction: Blood-brain barrier breakdown and cerebral hypoperfusion compound neuronal injury^{3Vascular Contributions to Alzheimer's Disease2023 · Nature Reviews Neurology · DOI 10.1038/s41582-023-00754-9Open reference}

The EU/US CTAD Task Force has formally concluded that monotherapy — even with the most effective anti-amyloid agents — cannot address the full complexity of AD, and that combination strategies are necessary to achieve the level of disease modification required for meaningful clinical impact^{4Alzheimer's disease2021 · Lancet · PMID 31952956Open reference5Combination Therapy in Alzheimer's Disease: Current Status2021 · CNS Drugs · PMID 34269873Open reference}.

Pharmacological Interactions: Synergy, Additivity, and Antagonism

Combination therapy can produce three types of interaction^{2Multi-target Drug Design for Neurodegenerative Diseases2022 · Nature Reviews Drug Discovery · PMID 35694825Open reference6Synergistic Effects of Combination Therapy in Parkinson's Disease2022 · Movement Disorders · PMID 35612847Open reference}:

• Synergistic: Combined effect exceeds the sum of individual effects. Example: anti-amyloid antibodies + TREM2 agonists may synergize because amyloid clearance requires functional, non-hyper-activated microglia to clear debris

• Additive: Combined effect equals the sum of individual effects. Example: disease-modifying agents + symptomatic treatments addressing independent disease dimensions

• Antagonistic: Combined effect is less than expected — a critical risk requiring factorial trial designs to detect

Lessons from Oncology and Infectious Disease

The success of combination therapy in cancer (checkpoint inhibitors + chemotherapy + targeted therapy) and HIV (triple antiretroviral therapy — HAART) provides a strong precedent^{7Alzheimer's disease drug development pipeline: 20242024 · Alzheimer's & Dementia · DOI 10.1002/alz.13956Open reference8Amyloid and Tau Dual Targeting for Alzheimer's Disease2023 · Nature Reviews Neurology · PMID 37098221Open reference}:

• In both fields, monotherapy led to resistance or escape; multi-target approaches were necessary for durable disease control

• Cancer therapy evolved from single-agent chemotherapy to rational combinations based on molecular profiling

• Neurodegeneration is following a similar trajectory, with biomarker-guided patient stratification enabling personalized combination selection

Anti-Amyloid + Anti-Tau Combinations

The Scientific Rationale

The anti-amyloid + anti-tau combination is the conceptually most compelling strategy, targeting both hallmark pathologies of AD^{9Neuroinflammation and Neuroprotection: Dual Therapeutic Approaches2023 · Pharmacological Reviews · PMID 37014592Open reference2Multi-target Drug Design for Neurodegenerative Diseases2022 · Nature Reviews Drug Discovery · PMID 35694825Open reference}0:

• Amyloid-beta drives the initiation phase of AD, but tau pathology correlates more closely with clinical decline and cognitive progression

• Clearing amyloid alone does not halt tau spreading and propagation; tau pathology can advance even after amyloid is cleared

• The two pathologies interact through multiple mechanisms: amyloid-induced microglial activation promotes tau phosphorylation; tau aggregates can accelerate amyloid deposition; both contribute to synaptic loss through distinct mechanisms

Clinical Trial Programs

DIAN-TU Platform (Dominantly Inherited Alzheimer Network)

The DIAN-TU is the leading platform for testing anti-amyloid + anti-tau combinations in genetic forms of AD:

• Study Design: 2x2 factorial trial testing anti-amyloid (lecanemab or semorinemab) + anti-tau (E2814, a tau ASO) in autosomal dominant AD mutation carriers

• Rationale: Genetic certainty and predictable disease course enable smaller trials with shorter follow-up

• Primary Endpoints: Biomarker changes (CSF tau, amyloid PET) and cognitive measures

• Status: Active enrollment, results anticipated 2026-2027

Tau ASO + Anti-Amyloid Combinations

The E2814 tau ASO (developed by Ionis and Eisai) targets the MAPT gene to reduce tau production:

• Phase 1/2: E2814 monotherapy demonstrated CSF tau reduction with acceptable safety

• Combination: DIAN-TU is testing E2814 + lecanemab; results expected at AAIC 2026

• Mechanism: Reducing tau synthesis may synergize with amyloid clearance to prevent downstream neurodegeneration

Anti-Tau Antibodies + Anti-Amyloid Antibodies

Multiple programs are testing anti-tau antibodies in combination with approved anti-amyloid agents:

Biomarker Considerations for Anti-Amyloid + Anti-Tau

Monitoring combinations requires tracking both pathologies independently:

• Amyloid PET or plasma p-tau217 for amyloid target engagement

• Tau PET (Fluoropyridine or MK-6240) for tau burden

• CSF p-tau181/t-tau for longitudinal monitoring

• Neurofilament light chain (NfL) for neurodegeneration progression

• Cognitive endpoints: CDR-SB, ADAS-Cog14, integrated AD score

Anti-Amyloid + Anti-Inflammatory Combinations

Rationale

Neuroinflammation accelerates disease progression independent of amyloid, and the neuroinflammatory response to amyloid clearance may limit the benefit of anti-amyloid monotherapy^{2Multi-target Drug Design for Neurodegenerative Diseases2022 · Nature Reviews Drug Discovery · PMID 35694825Open reference}1^{2Multi-target Drug Design for Neurodegenerative Diseases2022 · Nature Reviews Drug Discovery · PMID 35694825Open reference}2:

• Activated microglia drive synaptic pruning through the complement cascade, causing synapse loss even after plaques are cleared

• The NLRP3 inflammasome in microglia releases IL-1beta and other pro-inflammatory cytokines that promote tau pathology

• Reactive astrocytes adopt neurotoxic A1 phenotype, releasing toxic factors that kill neurons

• Blood-brain barrier dysfunction allows peripheral immune cells to infiltrate the CNS

TREM2 Agonists as Combination Partners

TREM2 agonists represent the most advanced anti-inflammatory approach for combination with anti-amyloid therapy^{2Multi-target Drug Design for Neurodegenerative Diseases2022 · Nature Reviews Drug Discovery · PMID 35694825Open reference}3:

Mechanism: TREM2 signaling promotes microglial survival, proliferation, and beneficial phagocytosis. TREM2 agonism may:

1. Enhance amyloid plaque clearance when combined with anti-amyloid antibodies

2. Shift microglia from disease-associated (DAM) to homeostatic state

3. Reduce complement-mediated synaptic pruning

4. Decrease NLRP3 inflammasome activation

AAIC 2026 expected updates: Phase 2 AL002 (INVOKE-2) results in TREM2 variant carriers, with planned combination cohorts with anti-amyloid agents.

Complement Inhibitors

The complement system is a compelling target for combination because complement-mediated synaptic pruning continues even after amyloid clearance^{2Multi-target Drug Design for Neurodegenerative Diseases2022 · Nature Reviews Drug Discovery · PMID 35694825Open reference}4:

Rationale: ANX005 (anti-C1q) combined with anti-amyloid therapy may reduce synaptic complement-mediated pruning that continues even after amyloid clearance. Phase 1b data showed good safety and biomarker target engagement; Phase 2 combination study with lecanemab is planned.

GLP-1 Receptor Agonist Combinations

GLP-1 receptor agonists address metabolic dysfunction and neuroinflammation through orthogonal mechanisms, making them logical combination partners:

• Semaglutide in the EVOKE Plus trial (3-year, 1,800+ patients) for early AD

• Liraglutide Phase 2b (ELAD trial) showed ~50% reduction in brain volume loss and up to 18% slower cognitive decline

• Combination potential: GLP-1 agonists address metabolic dysfunction, neuroinflammation, and insulin resistance — pathways orthogonal to anti-amyloid and anti-tau therapies^{2Multi-target Drug Design for Neurodegenerative Diseases2022 · Nature Reviews Drug Discovery · PMID 35694825Open reference}5

Multi-Target-Directed Ligands (MTDLs)

An alternative to multi-drug combinations is the design of single molecules that hit multiple targets^{2Multi-target Drug Design for Neurodegenerative Diseases2022 · Nature Reviews Drug Discovery · PMID 35694825Open reference}6:

Classes of MTDLs

• Dual AChE/MAO-B inhibitors: Ladostigil and ASS234 combine cholinesterase inhibition with monoamine oxidase inhibition in a single molecule

• Metal chelator-antioxidant hybrids: M30 and HLA20 combine iron chelation with radical scavenging and MAO inhibition — triple-action molecules for PD

• Anti-aggregation/anti-inflammatory hybrids: Single molecules that inhibit amyloid-beta aggregation while simultaneously modulating NF-kappaB-mediated inflammation

• A3 subtype-selective muscarinic agonists: Designed to simultaneously activate M1 receptors (cognitive) and antagonize M2 receptors (neuroprotection)

Advantages and Challenges

Advantages:

• Simplified pharmacokinetics — no drug-drug interactions

• Improved patient compliance (single pill vs. multiple agents)

• Synergistic multi-target effects from single molecule

• No regulatory complexity of combination product classification

Challenges:

• Achieving balanced potency across multiple targets

• Regulatory pathway uncertainty (novel compound vs. combination product)

• May not achieve the specificity of targeted biologics

Cell-Type-Directed Network-Correcting Combinations

A landmark 2024 Cell publication introduced a data-driven approach to combination therapy design using cell-type-specific transcriptomic networks^{2Multi-target Drug Design for Neurodegenerative Diseases2022 · Nature Reviews Drug Discovery · PMID 35694825Open reference}7:

The SEA-AD Approach

Approach: Integrated single-cell transcriptomics from SEA-AD and Allen Brain Cell Atlas with drug perturbation databases and electronic medical records from 1.4 million adults aged 65+ across six University of California health systems^{2Multi-target Drug Design for Neurodegenerative Diseases2022 · Nature Reviews Drug Discovery · PMID 35694825Open reference}8

Identified combination: Letrozole (aromatase inhibitor, used for breast cancer) targeting disease-associated gene expression in glial cells + irinotecan (topoisomerase inhibitor, used for colon/lung cancer) targeting neuronal disease networks

Preclinical results:

• In an AD mouse model with both amyloid and tau pathology, letrozole + irinotecan significantly improved memory performance

• Single-nucleus transcriptomic analysis confirmed cell-type-specific network reversal

• EMR analysis showed prior exposure to either drug was associated with lower AD incidence after propensity-matched adjustment

AAIC 2026 expected updates: Validation studies in human tissue, biomarker correlates, and planning for Phase 1/2 trials.

Clinical Trial Design for Combinations

Factorial Designs

The gold standard for testing combination contributions is the 2x2 factorial design^{2Multi-target Drug Design for Neurodegenerative Diseases2022 · Nature Reviews Drug Discovery · PMID 35694825Open reference}9:

            Drug B
         Placebo    Active
Placebo    Placebo  Drug B alone
  A        Drug A    Both drugs
         alone

This design allows:

• Independent assessment of each agent

• Detection of synergistic vs. additive effects

• Efficient sample size vs. four separate trials

Challenge: Requires 4x the sample size of a simple two-arm trial.

Adaptive Platform Trials

Platform trials enable efficient testing of multiple combinations with shared control arms^{3Vascular Contributions to Alzheimer's Disease2023 · Nature Reviews Neurology · DOI 10.1038/s41582-023-00754-9Open reference}0:

• DIAN-TU: Multi-arm platform testing anti-amyloid + anti-tau combinations

• GBM AGILE: Adaptive platform for brain disorders, enabling arm addition/dropping

• I-SPY-ALZ: Bayesian adaptive platform optimizing combination regimens

Biomarker-Enriched Designs

Biomarker-driven patient selection maximizes signal detection^{3Vascular Contributions to Alzheimer's Disease2023 · Nature Reviews Neurology · DOI 10.1038/s41582-023-00754-9Open reference}1:

• Amyloid-positive + tau-positive: Required for anti-amyloid + anti-tau combinations

• Inflammatory marker elevation: YKL-40, GFAP, or IL-6 for anti-inflammatory combination selection

• Genetic stratification: APOE4 carriers may have differential response to combinations

Basket Trials

Testing the same combination across multiple neurodegenerative diseases that share mechanisms:

• Anti-amyloid + anti-inflammatory combinations in AD, PD, and PSP

• Leverages common neuroinflammatory pathways across diseases

Phase-Specific Combination Strategies

Regulatory Considerations for Combination Therapies

Classification as Combination Products

A critical regulatory question is whether a combination constitutes a “combination product” under FDA regulations or is simply two separate drugs used together^{3Vascular Contributions to Alzheimer's Disease2023 · Nature Reviews Neurology · DOI 10.1038/s41582-023-00754-9Open reference}2:

• Fixed-dose combinations (single pill with two agents): Likely treated as a combination product, requiring single NDA

• Separate co-administered drugs: Each retains its own regulatory pathway; no combined approval needed

• Sequential therapy: Separate approvals for each phase of treatment

Accelerated Approval Pathway

The FDA’s accelerated approval pathway is particularly relevant for combinations^{3Vascular Contributions to Alzheimer's Disease2023 · Nature Reviews Neurology · DOI 10.1038/s41582-023-00754-9Open reference}3:

• Biomarker endpoints can serve as surrogate endpoints for approval if reasonably likely to predict clinical benefit

• Plasma p-tau217 as an acceptable endpoint for combinations targeting amyloid + tau

• Combined cognitive + biomarker endpoints increasingly accepted

International Regulatory Landscape

• EMA adaptive trial designs: European Medicines Agency has shown flexibility for combination product approval

• Japan PMDA: Has fast-tracked several combination programs for AD

• ICH harmonization: Ongoing efforts to align combination therapy regulatory requirements across jurisdictions

Specific Active Combination Trials

Anti-Amyloid + Anti-Inflammatory

Anti-Amyloid + Anti-Tau

Disease-Modifying + Symptomatic

Phased Combinations (Sequential)

Challenges and Safety Considerations

ARIA Risk in Combinations

Combining anti-amyloid antibodies with other immunomodulatory agents may increase the risk of ARIA (amyloid-related imaging abnormalities)^{3Vascular Contributions to Alzheimer's Disease2023 · Nature Reviews Neurology · DOI 10.1038/s41582-023-00754-9Open reference}4^{3Vascular Contributions to Alzheimer's Disease2023 · Nature Reviews Neurology · DOI 10.1038/s41582-023-00754-9Open reference}5:

• Anticoagulant use significantly increases ARIA-H (hemorrhage) risk — critical for combination with anti-inflammatory agents that affect coagulation

• Anti-inflammatory agents that modulate immune responses may synergize with anti-amyloid to increase ARIA-E (edema) risk

• Management: APOE4 carrier identification, baseline MRI, regular monitoring MRI, temporary drug discontinuation for ARIA

Drug-Drug Interactions

Multi-drug combinations require assessment of pharmacokinetic and pharmacodynamic interactions:

• CYP enzyme interactions between oral agents

• Competition for brain penetration via BBB transporters

• Synergistic or antagonistic target engagement at the protein level

Cumulative Toxicity

Long-term combination therapy raises concerns about:

• Cumulative ARIA risk over extended treatment periods

• Long-term immune modulation from anti-inflammatory agents

• Off-target effects from multi-target molecules (MTDLs)

Precision Medicine Approaches to Combination Selection

Genetic Stratification

APOE genotype significantly impacts both disease risk and treatment response

• APOE4 homozygotes: Highest risk, may benefit most from aggressive early combination therapy, but also highest ARIA risk

• APOE4 heterozygotes: Intermediate risk and response

• APOE4 non-carriers: May have different optimal combination strategies

Biomarker-Based Patient Selection

With the advent of blood-based biomarkers, precision combination selection is now feasible

• Plasma p-tau217: Highly specific for AD pathology; identifies patients most likely to respond to anti-amyloid + anti-tau combinations

• Neurofilament light chain (NfL): Identifies patients with ongoing neurodegeneration who may benefit from neuroprotective combinations

• GFAP: Marker of astrocyte reactivity; elevated levels may indicate patients who would benefit from anti-inflammatory combination components

Disease Stage-Based Sequencing

Related NeuroWiki Pages

Mechanism Pages

• Amyloid Cascade Pathway — Foundation for anti-amyloid therapy

• Neuroinflammation Pathway — Rationale for anti-inflammatory combinations

• Tau Seeding and Propagation — Target for anti-tau combinations

• TREM2 Signaling Pathway — TREM2 agonist rationale

• Complement System Pathway — Synaptic pruning and complement inhibition

• Synaptic Dysfunction in AD — Network effects beyond amyloid/tau

Therapeutic Pages

• Lecanemab — Approved anti-amyloid agent

• Donanemab — Approved anti-amyloid agent

• Tau-Targeted Therapeutics — Anti-tau pipeline

• Anti-Amyloid Immunotherapy — Broader anti-amyloid landscape

• Combination Therapy Approaches — General combination therapy page

• Biomarker-Guided Therapy — Precision combination selection

Event Pages

• AAIC 2026 Conference — Full AAIC 2026 coverage

• AAIC 2026: Clinical Trial Updates — Trial results summary

• AAIC 2026: Novel Therapeutic Targets — Emerging targets

• CTAD Conference — EU/US CTAD Task Force updates